{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:27:58Z","timestamp":1782174478040,"version":"3.54.5"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101118","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T11:47:14Z","timestamp":1690890434000},"page":"101118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline"],"prefix":"10.1016","volume":"62","author":[{"given":"Giovanni","family":"Di Minno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Spadarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Mauro","family":"Maldonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascia","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"De Cristofaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Follino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Guerrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101118_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjsurg.2018.01.011","article-title":"Association of shared decision-making on patient-reported health outcomes and healthcare utilization","volume":"216","author":"Hughes","year":"2018","journal-title":"Am J Surg"},{"key":"10.1016\/j.blre.2023.101118_bb0010","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2017.2148","article-title":"Out-of-pocket costs, financial distress, and underinsurance in cancer care","volume":"3","author":"Chino","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2023.101118_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pec.2013.10.031","article-title":"Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making","volume":"94","author":"Joseph-Williams","year":"2014","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.blre.2023.101118_bb0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/HCO.0000000000000322","article-title":"What to say and how to say it: effective communication for cardiovascular disease prevention","volume":"31","author":"Navar","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.blre.2023.101118_bb0025","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jacc.2015.01.043","article-title":"Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC\/AHA guidelines","volume":"65","author":"Martin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2023.101118_bb0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/pbc.25124","article-title":"Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia","volume":"62","author":"Crosby","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2023.101118_bb0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2023.101118_bb0040","doi-asserted-by":"crossref","first-page":"e27650","DOI":"10.2196\/27650","article-title":"Engaging caregivers and providers of children with sickle cell Anemia in shared decision making for hydroxyurea: protocol for a multicenter randomized controlled trial","volume":"10","author":"Hood","year":"2021","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.blre.2023.101118_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1958.tb03830.x","article-title":"Haemophilia and related conditions: a survey of 187 cases","volume":"4","author":"Biggs","year":"1958","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101118_bb0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11606-014-3074-8","article-title":"Navigating the unknown: shared decision-making in the face of uncertainty","volume":"30","author":"Berger","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.blre.2023.101118_bb0055","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1038\/s41467-020-20096-1","article-title":"Patient and public perspectives on cell and gene therapies: a systematic review","volume":"11","author":"Aiyegbusi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101118_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-022-02256-2","article-title":"The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the exigency study","volume":"17","author":"Fletcher","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2023.101118_bb0065","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/hae.14378","article-title":"An exploration of why men with severe haemophilia might not want gene therapy: the exigency study","volume":"27","author":"Fletcher","year":"2021","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S406894","article-title":"Gene therapy for hemophilia A: a mixed methods study of patient preferences and shared decision-making","volume":"17","author":"Limjoco","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2023.101118_bb0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.18502\/jovr.v15i3.7457","article-title":"Ocular gene therapy with adeno-associated virus vectors: current outlook for patients and researchers","volume":"15","author":"Casey","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.blre.2023.101118_bb0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000481129","article-title":"Health literacy: read all about it","volume":"2","author":"Horgan","year":"2017","journal-title":"Biomed Hub"},{"key":"10.1016\/j.blre.2023.101118_bb0085","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/PPA.S355627","article-title":"The hemophilia gene therapy patient journey: questions and answers for shared decision-making","volume":"16","author":"Wang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2023.101118_bb0090","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/PPA.S239810","article-title":"The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients","volume":"14","author":"Miesbach","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2023.101118_bb0095","doi-asserted-by":"crossref","first-page":"100759","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: a guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0100","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3324\/haematol.2016.156000","article-title":"Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine","volume":"102","author":"Di Minno","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101118_bb0105","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1001\/jama.2015.3595","article-title":"The precision medicine initiative: a new national effort","volume":"313","author":"Ashley","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2023.101118_bb0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1037\/0278-6133.15.6.423","article-title":"What is the relationship between breast cancer risk and mammography screening? A meta-analytic review","volume":"15","author":"McCaul","year":"1996","journal-title":"Health Psychol"},{"key":"10.1016\/j.blre.2023.101118_bb0115","first-page":"CD003751","article-title":"Communication skills training for healthcare professionals working with people who have cancer","volume":"7","author":"Moore","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0120","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/pon.4063","article-title":"How doctors communicate the initial diagnosis of cancer matters: cancer disclosure and its relationship with patients\u2019 hope and trust","volume":"26","author":"Cao","year":"2017","journal-title":"Psychooncology"},{"key":"10.1016\/j.blre.2023.101118_bb0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13023-020-01555-w","article-title":"Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study","volume":"16","author":"Hart","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2023.101118_bb0130","series-title":"Communicating with patients on health care evidence","author":"Alston","year":"2012"},{"key":"10.1016\/j.blre.2023.101118_bb0135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.blre.2018.08.003","article-title":"Attempting to remedy sub-optimal medication adherence in haemophilia: the rationale for repeated ultrasound visualisations of the patient\u2019s joint status","volume":"33","author":"Di Minno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0140","first-page":"CD001431","article-title":"Decision aids for people facing health treatment or screening decisions","author":"Stacey","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1302","article-title":"Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks","volume":"350","author":"Spertus","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2023.101118_bb0150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/M14-0295","article-title":"Evidence-based risk communication: a systematic review","volume":"161","author":"Zipkin","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2023.101118_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/ijn.12610","article-title":"Perceptions of risk of coronary heart disease among people living with type 2 diabetes mellitus","volume":"24","author":"Ammouri","year":"2018","journal-title":"Int J Nurs Pract"},{"key":"10.1016\/j.blre.2023.101118_bb0160","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2023.101118_bb0165","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2023.101118_bb0170","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using National Registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2023.101118_bb0175","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.3324\/haematol.2020.267427","article-title":"Convalescent plasma for administration of passive antibodies against viral agents","volume":"105","author":"Di Minno","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101118_bb0180","doi-asserted-by":"crossref","first-page":"101011","DOI":"10.1016\/j.blre.2022.101011","article-title":"Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy","volume":"58","author":"Di Minno","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0185","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101118_bb0190","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101118_bb0195","first-page":"3668","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during Emicizumab prophylaxis: analyses from the HAVEN 1 study","volume":"130","author":"Callaghan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0200","first-page":"100618","article-title":"Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine","author":"Spadarella","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0205","first-page":"138","article-title":"Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies","author":"Howard","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101118_bb0210","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Maria","year":"2023","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2023.101118_bb0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/17474086.2018.1423961","article-title":"Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick","volume":"11","author":"Machin","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2023.101118_bb0220","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0225","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0230","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jim\u00e9nez-Yuste","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2023.101118_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2023.101118_bb0240","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1182\/blood-2009-07-215665","article-title":"How I treat age-related morbidities in elderly persons with hemophilia","volume":"114","author":"Mannucci","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 6","key":"10.1016\/j.blre.2023.101118_bb0245","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13489","article-title":"Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes","volume":"24","author":"Pierce","year":"2018","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.blre.2023.101118_bb0255","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/aje\/kwm030","article-title":"Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990","volume":"165","author":"Goedert","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.blre.2023.101118_bb0260","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2011.10.022","article-title":"Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection","volume":"93","author":"Svicher","year":"2012","journal-title":"Antivir Res"},{"key":"10.1016\/j.blre.2023.101118_bb0265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2010.08263.x","article-title":"Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: Towards evidence-based approaches","volume":"150","author":"Coppola","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101118_bb0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0275","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12185-009-0435-x","article-title":"Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS\/Bayer","volume":"90","author":"Lusher","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2023.101118_bb0280","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0285","first-page":"7","article-title":"Perspective on adenoviruses: epidemiology, pathogenicity, and gene therapy","author":"Crenshaw","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2023.101118_bb0290","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0295","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2023.101118_bb0300","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.omtm.2020.11.015","article-title":"Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors","volume":"20","author":"Ferla","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2023.101118_bb0305","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0310","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.omtm.2019.08.015","article-title":"Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer","volume":"15","author":"Pipe","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2023.101118_bb0315","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101118_bb0320","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"7\u20138","key":"10.1016\/j.blre.2023.101118_bb0325","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0330","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","article-title":"Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-gamma ELISpot method","volume":"22","author":"Patton","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2023.101118_bb0335","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.blre.2023.101118_bb0340","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-61779-370-7_11","article-title":"Measuring immune responses to recombinant AAV gene transfer","volume":"807","author":"Martino","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.blre.2023.101118_bb0350","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for hemophilia a","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0355","article-title":"Efficacy and safety of valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from the phase 3 GENEr8\u20131 trial. Oral presentation at ISTH 2021 Congress","volume":"5","author":"Ozelo","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101118_bb0360","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101118_bb0365","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2040620718791933","article-title":"Gene therapy for hemophilia: What does the future hold?","volume":"9","author":"Doshi","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2023.101118_bb0370","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0375","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","article-title":"Progress and challenges in viral vector manufacturing","volume":"25","author":"van der Loo","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.blre.2023.101118_bb0380","first-page":"10","article-title":"Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia","author":"Monahan","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2023.101118_bb0385","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101118_bb0390","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with Etranacogene Dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0395","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2006.17.440","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors","volume":"17","author":"Halbert","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0400","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1128\/JVI.73.5.4293-4298.1999","article-title":"Adeno-associated virus (AAV) type 5 rep protein cleaves a unique terminal resolution site compared with other AAV serotypes","volume":"73","author":"Chiorini","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2023.101118_bb0405","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2023.101118_bb0415","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2023.101118_bb0420","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2023.101118_bb0425","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.blre.2023.101118_bb0430","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.blre.2023.101118_bb0435","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.blre.2023.101118_bb0440","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2023.101118_bb0445","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.blre.2020.100737","article-title":"The evolving landscape of gene therapy for congenital haemophilia: an unprecedented, problematic but promising opportunity for worldwide clinical studies","volume":"46","author":"Spadarella","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0450","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0455","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2023.101118_bb0460","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2009-04-217075","article-title":"Is VIII worse than IX?","volume":"114","author":"Makris","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0465","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/hae.12133","article-title":"Is haemophilia B less severe than haemophilia A?","volume":"19","author":"Mannucci","year":"2013","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0470","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJM198204013061306","article-title":"Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty","volume":"306","author":"Briet","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0475","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2023.101118_bb0480","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012551","article-title":"The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment","volume":"97","author":"Qvigstad","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.blre.2023.101118_bb0485","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrgastro.2016.140","article-title":"Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC","volume":"13","author":"Llovet","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2023.101118_bb0490","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2023.101118_bb0495","first-page":"10","article-title":"Noninvasive tests (NITs) for hepatic fibrosis in fatty liver syndrome","author":"Han","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.blre.2023.101118_bb0500","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jmri.23731","article-title":"Magnetic resonance elastography of liver: technique, analysis, and clinical applications","volume":"37","author":"Venkatesh","year":"2013","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.blre.2023.101118_bb0505","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2023.101118_bb0510","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2023.101118_bb0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/156652309787909490","article-title":"Hepatic gene transfer as a means of tolerance induction to transgene products","volume":"9","author":"LoDuca","year":"2009","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0520","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0525","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0530","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0535","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0540","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.blre.2023.101118_bb0545","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/hae.13717","article-title":"The national blueprint for future factor VIII inhibitor clinical trials: NHLBI state of the science (SOS) workshop on factor VIII inhibitors","volume":"25","author":"Ragni","year":"2019","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0550","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0555","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"Ljung","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101118_bb0560","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/hae.14431","article-title":"Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors","volume":"28","author":"Di Minno","year":"2022","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0570","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the international immune tolerance study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101118_bb0575","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2174\/138161211797247541","article-title":"Perinatal gene transfer to the liver","volume":"17","author":"McKay","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.blre.2023.101118_bb0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.blre.2023.101118_bb0585","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jmv.23818","article-title":"The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals","volume":"86","author":"Mimuro","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.blre.2023.101118_bb0590","first-page":"602","article-title":"Gene therapy for hemophilia: progress to date and challenges moving forward","volume":"58","author":"Gollomp","year":"2019","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"10.1016\/j.blre.2023.101118_bb0595","first-page":"55","article-title":"Body length and organ weights of infants and children: a study of the body length and Normal weights of the more important vital organs of the body between birth and twelve years of age","volume":"9","author":"Coppoletta","year":"1933","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2023.101118_bb0600","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2040620717746312","article-title":"Novel therapies and current clinical progress in hemophilia a","volume":"9","author":"Balkaransingh","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2023.101118_bb0605","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/hae.12341","article-title":"Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues","volume":"20","author":"Carvalhosa","year":"2014","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0610","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.blre.2023.101118_bb0615","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/hae.13769","article-title":"How to discuss gene therapy for haemophilia? A patient and physician perspective","volume":"25","author":"Miesbach","year":"2019","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0620","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.13754","article-title":"From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies","volume":"25","author":"Wiley","year":"2019","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0625","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hae.13621","article-title":"Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a qualitative review","volume":"24","author":"Lee Mortensen","year":"2018","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0630","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2023.101118_bb0635","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2516.2011.02741.x","article-title":"A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center","volume":"18","author":"Dodd","year":"2012","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0640","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.12533","article-title":"Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey","volume":"21","author":"Krishnan","year":"2015","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0645","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0036-1579640","article-title":"Assessment of hemophilic Arthropathy by ultrasound: where do we stand?","volume":"42","author":"Di Minno","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2023.101118_bb0650","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1365-2141.2000.02507.x","article-title":"Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease","volume":"111","author":"Lak","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101118_bb0655","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of Valoctocogene Roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0660","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.blre.2021.100885","article-title":"Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement","volume":"51","author":"Santoro","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0665","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/PROM.S211339","article-title":"Hemophilia and sexual health: results from the HERO and B-HERO-S studies","volume":"10","author":"Blamey","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.blre.2023.101118_bb0670","first-page":"e287","article-title":"Haemophilia experiences, results and opportunities (HERO) study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia","volume":"20","author":"Cassis","year":"2014","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0675","first-page":"e101","article-title":"Psychosocial aspects of haemophilia: a systematic review of methodologies and findings","volume":"18","author":"Cassis","year":"2012","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0680","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.blre.2023.101118_bb0685","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia a","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0690","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/hae.13214","article-title":"Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the pain, functional impairment, and quality of life (P-FiQ) study","volume":"23","author":"Witkop","year":"2017","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0695","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0700","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/hae.13600","article-title":"Pain assessment and management in haemophilia: a survey among Italian patients and specialist physicians","volume":"24","author":"Tagliaferri","year":"2018","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0705","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/MBC.0000000000000571","article-title":"Pain and pain management in haemophilia","volume":"27","author":"Auerswald","year":"2016","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.blre.2023.101118_bb0710","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/PPA.S212723","article-title":"Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey","volume":"13","author":"Witkop","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2023.101118_bb0715","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.4081\/hr.2019.7894","article-title":"Health status and quality of life in patients with severe hemophilia A: a cross-sectional survey","volume":"11","author":"Davari","year":"2019","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2023.101118_bb0720","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hae.13731","article-title":"Health-related quality of life and health status in persons with haemophilia a with inhibitors: a prospective, multicentre, non-interventional study (NIS)","volume":"25","author":"Mahlangu","year":"2019","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0725","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O\u2019Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.blre.2023.101118_bb0730","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/13696998.2020.1721508","article-title":"Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A","volume":"23","author":"Cook","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.blre.2023.101118_bb0735","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221145627","article-title":"How to translate and implement the current science of gene therapy into haemophilia care?","volume":"14","author":"Hermans","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101118_bb0740","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/hae.14766","article-title":"The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: analysis of the CHESS population studies","volume":"29","author":"Chowdary","year":"2023","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0745","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1748-5908-3-36","article-title":"Healthcare professionals\u2019 intentions and behaviours: a systematic review of studies based on social cognitive theories","volume":"3","author":"Godin","year":"2008","journal-title":"Implement Sci"},{"key":"10.1016\/j.blre.2023.101118_bb0750","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MBC.0000000000001130","article-title":"The role of thrombin in haemostasis","volume":"33","author":"Al-Amer","year":"2022","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.blre.2023.101118_bb0755","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2741\/4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.blre.2023.101118_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mt.2012.272","article-title":"Gene therapy for hemophilia: addressing the coming challenges of affordability and accessibility","volume":"21","author":"Skinner","year":"2013","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.blre.2023.101118_bb0765","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0770","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia Off J World Fed Hemophilia"},{"key":"10.1016\/j.blre.2023.101118_bb0775","first-page":"14","article-title":"Toward more comprehensive homologous recombination deficiency assays in ovarian Cancer part 2: medical perspectives","author":"Quesada","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2023.101118_bb0780","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.blre.2021.100849","article-title":"Perspective - the case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia a in 2021","volume":"50","author":"Di Minno","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101118_bb0785","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101118_bb0790","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/0272989X9501500105","article-title":"Validation of a decisional conflict scale","volume":"15","author":"O\u2019Connor","year":"1995","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.blre.2023.101118_bb0795","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pec.2009.07.009","article-title":"Developing a dyadic OPTION scale to measure perceptions of shared decision making","volume":"78","author":"Melbourne","year":"2010","journal-title":"Patient Educ Couns"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:32:28Z","timestamp":1759437148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":159,"alternative-id":["S0268960X23000796"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101118","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101118"}}